“Role of NICOTINE REPLACEMENT THERAPY (NRT) to Quit Smoking” SUMMER INTERNSHIP (June- July) Submitted for the Partial Fulfillment of MBA (Biotechnology Management) Degree Of AMITY UNIVERSITY, UTTAR PRADESH Julee Gogoi A0500108023 Under the Supervision of Mr. Gaurav Gupta (Business manager) Cipla Pvt. Ltd, New Delhi AMITY INSTITUTE OF BIOTECHNOLOGY AMITY UNIVERSITY, UTTAR PRADESH SECTOR 125, NOIDA- 201303, UTTAR PRADESH, INDIA 2009 ACKNOWLEDGEMENT 1 “TO THE ALMIGHTY FOR THE ASPIRATION AND INSPIRATION” It is our honors to state that we are very grateful to our institution AMITY UNIVERSITY for envisaging such a stupendous project. At the outset, I would like to place on record my gratitude to all those who have been instrumental in shaping up this project with their guidance and inspiration. I express my hearty respect and profound thanks to Mr. Gaurav Gupta for his valuable guidance in completing my project and also his sincere cooperation in directing and guiding me enabled the project to assume its systematic shape. Last but not the least I must express my gratitude to my family and various friends who gave moral support for completing this project work. Julee Gogoi MBT/08/1027 TABLE OF CONTENTS 1. Certificate…………………………………………….. …………1 2 2. Acknowledgement……………………………………………. .2 3. Table of contents………………………………………………..3 4. Executive Summary…………………………………………….5 5. Introduction……………………………………………………..6-31 5.1 Company profile 5.2 History 5.3 Vision 5.4 Cipla products 5.5 Cipla in the market 5.6 Swot Analysis 5.7 Strategic tie ups 5.8 Achievements 5.9 Awards 6. Objective and Rationale of the project………………………32 7. Literature Review……………………………………………….34-48 7.1 Introduction to the study 3 7.2 What is smoking? 7.3 Nicotine Replacement Therapy (NRT) 7.4 What is Nicotex? 8. Research Methodology…………………………………………49 9. Data Analysis……………………………………………………53 10. Limitations…………………………................. ………………..61 11. Conclusions……………………………………………………..62 12. Recommendations……………………………………………...64 13. References……………………………………………………….65 14. Appendix (questionnaire)……………………………………..66 4 EXECUTIVE SUMMARY The project work thoroughly looks into the adverse affects of smoking and also those who take tobacco directly. The main culprit causing such deleterious effects on the human body was thought to be nicotine. It causes diseases like lung cancer, hypertension, asthma, bladder cancer, throat cancer, stroke of central nervous system. There are about 1.2 billion smokers in the world, in which half of them are supposed to die by the diseases caused by smoking.This report aims at drawing a picture of peoples attitudes towards smoking, exposure to passive smoking and provision of cigarettes across an area. Unless stated otherwise, in this report the term ‘current smokers’ includes both occasional smokers (less than 1 cigarette a day) and regular smokers (more than 1 cigarette a day). The introduction of Nicotine Replacement Therapy (NRT), the most recent U.S. Department of Health and Human Services (DHHS) recommended NRT for first line treatment to cut down addiction has successfully led to a decrease in the mortality and morbidity and to better quality of life in tobacco smokers. NRT is available in various formulations like transdermal patch, chewing gum, nasal spray, inhaler and lozenge. Most of the studies were performed in people smoking more than 15 cigarettes a day. The limited evidence suggests that there is overall difference in effectiveness of different forms of NRT or a benefit for using patches beyond 8 weeks. NRT works with or without additional counseling, and does not need to be prescribed by a doctor. Heavier smokers may need higher doses of NRT. People who use NRT during a quit attempt are likely to further increase their chance of success by using a combination of the nicotine patch and a faster acting form. Preliminary data suggests that starting to use NRT shortly before the planned quit date may increase the chance of success. Adverse effects from using NRT are related to the type of product, and include skin irritation from patches and irritation to the inside of the mouth from gum and tablets. There is no evidence that NRT increases the risk of heart attacks. 5 INTRODUCTION The government has identified tobacco control as a key part of its approach to improving health and reducing inequalities. People need to be protected from the harmful effects of tobacco through education, legislation, cessation support and provision of smoke free environments. In order for appropriate intervention mechanisms to be developed and their effectiveness to be measured, it is essential that we obtain data on current smoking prevalence, attitudes and trends. For planners of services and interventions, this data must be developed into useful information demonstrating the various issues related to tobacco usage. This report aims at drawing a picture of peoples attitudes toward smoking, exposure to passive smoking and provision of cigarettes across an area. Unless stated otherwise, in this report the term ‘current smokers’ includes both occasional smokers (less than 1 cigarette a day) and regular smokers (more than 1 cigarette a day). Cigarette smoking is a modern epidemic. This legal addiction has its origins in childhood and once established is extremely difficult to reverse. The rate of smokers are increasing and mostly targeting the youngsters. Smoking among the adults are more than the elders due to unawareness among the youngsters and the misconception of feel good factor. This is due to the presence of nicotine in the cigarettes and gutkha. It was found that nicotine is a cause of addiction. 45% among them are females who smoke for loosing weight and to look beautiful. COMPANY PROFILE 6 Founded 1935 Headquarters Mumbai, India “There’ll Key people Y. K. Hamied (CMD), Chairman always be a Industry Pharmaceuticals healthier way Revenue ▲ Rs. 37.6 billion (~939M USD) (2006) to live, a Net income ▲ Rs. 9.1 billion (2006) warmer way to Employees over 7,000 care, a surer Website http://www.cipla.com/ way to heal, a calmer way to sleep. There’ll always be a better world, for those who have the passion to create it”. That’s been Cipla’s belief since 1935, when it began as a small Indian enterprise committed to the nation’s quest for self-sufficiency. The War that followed saw Cipla rise to the challenge of meeting the alarming shortage of essential medicines. Over the years their commitment to heal, protect and enrich lives has only grown, and so have their capabilities. Cipla, originally founded as The Chemical, Industrial & Pharmaceutical Laboratories is a prominent Indian pharmaceutical company, best-known outside its home country for producing low-cost anti-AIDS drugs for HIV-positive patients in developing countries. Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in more than 180 countries worldwide HISTORY Khwaja Abdul Hamied, the founder of Cipla, was born on October 31, 1898. The fire of nationalism was kindled in him 7 when he was 15 as he witnessed a wanton act of colonial highhandedness. The fire was to blaze within him right through his life. CIPLA IS BORN In 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla. He gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs. The search for suitable premises ended at 289, Bellasis Road (the present corporate office) where a small bungalow with a few rooms was taken on lease for 20 years for Rs 350 a month. Cipla was officially opened on September 22, 1937 when the first products were ready for the market. The Sunday Standard wrote: "The birth of Cipla which was launched into the world by Dr K A Hamied will be a red letter day in the annals of Bombay Industries. The first city in India can now boast of a concern, which will supersede all existing firms in the magnitude of its operations. India has lagged behind in the march of science but she is now awakening from her lethargy. The new company has mapped out an ambitious programme and with intelligent direction and skillful production bids fair to establish a great reputation in the East. " MAHATMA GANDHI VISITS CIPLA Mahatma Gandhi visits Cipla (July 4th 1939) 8 July 4, 1939 was a red-letter day for Cipla, when the Father of the Nation, Mahatma Gandhi, honoured the factory with a visit. He was "delighted to visit this Indian enterprise", he noted later. From the time Cipla came to the aid of the nation gasping for essential medicines during the Second World War, the company has been among the leaders in the pharmaceutical industry in India. On October 31, 1939, the books showed an alltime high loss of Rs 67,935. That was the last time the company ever recorded a deficit. In 1942, Dr Hamied's blueprint for a technical industrial research institute was accepted by the government and led to the birth of the Council of Scientific and Industrial Research (CSIR), which is today the apex research body in the country. 9 In 1944, the company bought the premises at Bombay Central and decided to put up a "first class modern pharmaceutical works and laboratory." It was also decided to acquire land and buildings at Vikhroli. With severe import restrictions hampering production, the company decided to commence manufacturing the basic chemicals required for pharmaceuticals. In 1946, Cipla's product for hypertension, Serpinoid , was exported to the American Roland Corporation, to the tune of Rs 8 lakhs. Five years later, the company entered into an agreement with a Swiss firm for manufacturing foromycene. Dr Yusuf Hamied, the founder's son, returned with a doctorate in chemistry from Cambridge and joined Cipla as an officer in charge of research and development in 1960.